<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Powers, Jenny</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kay, Jonathan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Biosimilar and Orphan Drugs in Treating Patients with Rheumatologic Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-8</style></pages><abstract><style  face="normal" font="default" size="100%">Biosimilar drugs may offer affordable targeted therapies to patients across a spectrum of rheumatologic, oncologic, and gastrointestinal diseases, but they pose unique clinical trial design and licensing issues. Governments provide incentives for developing orphan drugs that would not otherwise be cost-effective to manufacture, allowing for the possibility of effective treatment options for rare diseases, including many rheumatologic conditions.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>